## Abstract To evaluate the efficacy of rivastigmine on motor and cognitive impairment in Huntington's disease (HD), we carried out a prospective, openβlabel, randomized, controlled study. Twentyβone HD patients were enrolled: 14 were randomly sorted into medication and 7 to noβtreatment groups. Cl
A comparison of two brief screening measures of cognitive impairment in Huntington's disease
β Scribed by Laura Mickes; Mark Jacobson; Guerry Peavy; John T. Wixted; Stephanie Lessig; Jody L. Goldstein; Jody Corey-Bloom
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 459 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The goal of this study was to explore whether the Montreal Cognitive Assessment (MoCA), a new screening instrument, would be more sensitive to mild to moderate cognitive impairment in Huntington's disease (HD) than an established screening measure, the Mini Mental State Exam (MMSE). Our reasoning for this query is that the MoCA includes a broader range of test items and an additional assessment of executive functioning and attention compared with the MMSE. Using the receiver operating characteristic (ROC) analysis to examine performance of HD and control groups on both tests on overall scores and scores from various subdomains (i.e., visuospatial abilities) revealed that the MoCA achieved higher sensitivity without sacrificing specificity in many domains relative to the MMSE. Β© 2010 Movement Disorder Society
π SIMILAR VOLUMES
We read with interest the article by Dujardin et al., in which the investigators aimed to design a simple neuropsychological battery able to easily and accurately screen for dementia in Parkinson's disease (PDD) in routine clinical practice. 1 Brief cognitive tests have been developed in the field o
We performed positron emission tomographic (YET) measurements of the regional distribution volume of benzodiazepine receptors and regional glucose metabolism in 6 drug-free patients with early Huntington's disease following injection of EL1C}tlumazenil, a nonsubtype selective central benzodiazepine